Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07469735) titled 'Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma' on March 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Huashan Hospital
Condition:
Glioma
Diffuse Glioma
Recurrent Gliomas
Intervention:
Drug: Oral Vorasidenib administered once daily for up to 12 treatment cycles (28 days per cycle) as IDH-targeted therapy in participants with recurrent or residual IDH-mutant diffuse glioma.
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: April 1, 2026
Ta...